Contributors

Salvatore Alesci, M.D., Ph.D., Wyeth Research, Collegeville, Pennsylvania

Robert Balshaw, Ph.D., Syreon Corporation, Vancouver, British Columbia, Canada

Eric J. Baude, Ph.D., Brinks Hofer Gilson & Lione, P.C., Ann Arbor, Michigan

Sven A. Beushausen, Ph.D., Pfizer Global Research and Development, Chesterfield, Missouri

Michael R. Bleavins, Ph.D., DABT, Michigan Technology and Research Institute, Ann Arbor, Michigan

Cynthia M. Bott, Ph.D., Honigman Miller Schwartz and Cohn LLP, Ann Arbor, Michigan

Jacquelyn Brinkman, M.Sc., University of British Columbia, Vancouver, British Columbia, Canada

Alan P. Brown, Ph.D., DABT, Pfizer Global Research and Development, Ann Arbor, Michigan

Michael Burgess, Ph.D., University of British Columbia, Vancouver, British Columbia, Canada

Bruce D. Car, B.V.Sc., Ph.D., Bristol-Myers Squibb Co., Princeton, New

Jersey

Daniel Chelsky, Ph.D., Caprion Proteomics, Inc., Montreal, Quebec, Canada

Claire Cornips, B.Sc., Utrecht University, Utrecht, The Netherlands

Kay A. Criswell, Ph.D., Pfizer Global Research and Development, Groton, Connecticut

Ian Dews, MRCP, FFPM, Envestia Ltd., Thame, Oxfordshire, UK

Gregory J. Downing, D.O., Ph.D., U.S. Department of Health and Human Services, Washington, DC

Dominic Eisinger, Ph.D., Rules Based Medicine, Inc., Austin, Texas

Deborah Elstein, Ph.D., Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel

Giora Z. Feuerstein, M.D., Wyeth Research, Collegeville, Pennsylvania

Edward P. Ficaro, Ph.D., INVIA Medical Imaging Solutions, Ann Arbor, Michigan

Shawna Flynn, B.Sc., Syreon Corporation, Vancouver, British Columbia, Canada

William R. Foster, Ph.D., Bristol - Myers Squibb Co., Princeton, New

Jersey

Candida Fratazzi, M.D., Altus Pharmaceuticals, Inc., Waltham, Massachusetts

Keith Gallicano, Ph.D., Watson Laboratories, Corona, California

Brian Gemzik, Ph.D., Bristol-Myers Squibb Co., Princeton, New Jersey

Alberto Gimona, M.D., Merck Serono International, Geneva, Switzerland

Federico Goodsaid, Ph.D., Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland

Steven Gutman, M.D., M.B.A., University of Central Florida, Orlando, Florida; formerly with the U.S. Food and Drug Administration, Rockville, Maryland

Richard Hegele, M.D., Ph.D., University of British Columbia, Vancouver, British Columbia, Canada

Michael Hehenberger, Ph.D., IBM Healthcare & Life Sciences, Somers, New York

Joanna M. Hunter, Ph.D., Caprion Proteomics, Inc., Montreal, Quebec, Canada

Nita Ichhpurani, B.A., PMP, MDS Pharma Services, Mississauga, Ontario, Canada

Kent J. Johnson, M.D., The University of Michigan Medical School, Ann Arbor, Michigan

Thomas Joos, Ph.D., Rules Based Medicine, Inc., Austin, Texas

Malle Jurima-Romet, Ph.D., MDS Pharma Services, Montreal, Quebec, Canada

CONTRIBUTORS xi

Francis Kalush, Ph.D., U.S. Food and Drug Administration, Silver Spring, Maryland; formerly with USFDA, Rockville, Maryland

Paul Keown, M.D., D.Sc., MBA, University of British Columbia, Vancouver, British Columbia, Canada

Anthony A. Killeen, M.D., Ph.D., University of Minnesota, Minneapolis, Minnesota

Lena King, Ph.D., DABT, CanBioPharma Consulting, Inc., Guelph, Ontario, Canada

Lars Klareskog, M.D., Ph.D., Karolinska Institute, Stockholm, Sweden

Jean W. Lee, Ph.D., Amgen, Inc., Thousand Oaks, California

Xiaowu Liang, Ph.D., Antigen Discovery, Inc., Irvine, California

David Lin, B.MLSc., University of British Columbia, Vancouver, British Columbia, Canada

Klaus Lindpaintner, M.D., M.P.H., F. Hoffmann-La Roche AG, Basel, Switzerland

Bruce H. Littman, M.D., Translational Medicine Associates, Stonington, Connecticut

Calvert Louden, Ph.D., Johnson & Johnson Pharmaceuticals, Raritan, New

Jersey

J.F. Marier, Ph.D., FCP, Pharsight, A Certara Company, Montreal, Quebec, Canada

William B. Mattes, Ph.D., DABT, The Critical Path Institute, Rockville, Maryland

Ralph McDade, Ph.D., Rules Based Medicine, Inc., Austin, Texas

Bruce McManus, M.D., Ph.D., University of British Columbia, Vancouver, British Columbia, Canada

Robert McMaster, D.Phil., University of British Columbia, Vancouver, British Columbia, Canada

Douglas M. Molina, Ph.D., Antigen Discovery, Inc., Irvine, California

Jonathan B. Moody, Ph.D., INVIA Medical Imaging Solutions, Ann Arbor, Michigan

W. John W. Morrow, Ph.D., Antigen Discovery, Inc., Irvine, California

Philip S. Murphy, Ph.D., GlaxoSmithKline Research and Development, Uxbridge, Middlesex, UK

Raymond Ng, Ph.D., University of British Columbia, Vancouver, British Columbia, Canada

Amadeo M. Parissenti, Ph.D., Laurentian University, Sudbury, Ontario, Canada

J. Fred Pritchard, Ph.D., MDS Pharma Services, Raleigh, North Carolina

Ramin Rahbari, M.S., Innovative Scientific Management, New York, New York

Joshua Reineke, Ph.D., Wayne State University, Detroit, Michigan

Charles W. Richard, III, M.D., Ph.D., Shire Human Genetic Therapies, Cambridge, Massachusetts

Ruth A. Roberts, Ph.D., AstraZeneca Research and Development, Macclesfield, UK

Robert R. Ruffolo, Jr., Ph.D., Wyeth Research, Collegeville, Pennsylvania

J. Lynn Rutkowski, Ph.D., Wyeth Research, Collegeville, Pennsylvania

Huub Schellekens, M.D., Utrecht University, Utrecht, The Netherlands

Andreas Scherer, Ph.D., Spheromics, Kontiolahti, Finland

Frank D. Sistare, Ph.D., Merck Research Laboratories, West Point, Pennsylvania

Whaijen Soo, M.D., Ph.D., Shire Human Genetic Therapies, Cambridge, Massachusetts

Jason A. Sprowl, Ph.D., Laurentian University, Sudbury, Ontario, Canada

John F. Thompson, M.D., Helicos BioSciences, Cambridge, Massachusetts

Christina Trollmo, Ph.D., Karolinska Institute and Roche AB Sweden, Stockholm, Sweden

Donald C. Trost, M.D., Ph.D., Analytic Dynamics, Niantic, Connecticut

Arthur O. Tzianabos, Ph.D., Shire Human Genetic Therapies, Cambridge, Massachusetts

James Varani, Ph.D., The University of Michigan Medical School, Ann Arbor, Michigan

Heather Walmsley, M.A., Lancaster University, Bailrigg, Lancaster, UK

Frank L. Walsh, Ph.D., Wyeth Research, Collegeville, Pennsylvania

Jin Wang, M.S., Amgen, Inc., Thousand Oaks, California

Peter A. Ward, M.D., The University of Michigan Medical School, Ann Arbor, Michigan

CONTRIBUTORS xiii

Craig P. Webb, Ph.D., Van Andel Research Institute, Grand Rapids, Michigan

Janet Wilson - McManus, M.T., B.Sc., University of British Columbia, Vancouver, British Columbia, Canada

Yuling Wu, Ph.D., Amgen, Inc., Thousand Oaks, California

Mary Zacour, Ph.D., BioZac Consulting, Montreal, Quebec, Canada

Ari Zimran, M.D., Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel

Cure Your Yeast Infection For Good

Cure Your Yeast Infection For Good

The term vaginitis is one that is applied to any inflammation or infection of the vagina, and there are many different conditions that are categorized together under this ‘broad’ heading, including bacterial vaginosis, trichomoniasis and non-infectious vaginitis.

Get My Free Ebook


Post a comment